课题基金 / 基金详情

Translational Research in Biomaterials

Translational Research in Biomaterials
生物材料转化研究
批准号:
10259674
负责人:
MARK W. GRINSTAFF
金额:
$19.97万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-09 至 2022-08-31

项目摘要

项目成果

MARK W. GRINSTAFF的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT This application proposes the second renewal of Boston University's NIH training program, Translational Research in Biomaterials (TRB). The mission of the TRB is to develop PhD students into interdisciplinary and translational research scientists and engineers. Through their TRB training, students acquire a fundamental and quantitative understanding of materials, surface science, biomaterial-tissue response, and molecular and cell biology, as well as training experiences in interdisciplinary programs that promote discussion and scientific inquiry in areas outside students’ “comfort zones.” New for this renewal are: a junior faculty mentoring plan, integrated student governance, better data collection, and more targeted efforts for underrepresented minority recruitment. Furthermore, we expand the educational, research, and training opportunities for TRB Fellows to include BU’s NSF ERC in Cellular Metamaterials and partnerships with Massachusetts General Hospital and Beth Israel Deaconess Medical Center. The cornerstones of the TRB program are the curriculum and the program elements that combine interdisciplinary research, quantitative science, engineering, and translational-based courses in clinical trials and business, with student-organized seminar club, dinners with clinicians, training in professional ethics, individual career plans, and professional development workshops. Our aim is to teach the unique skills and competencies that are essential to thrive in a multidisciplinary collaborative team striving to meet common goals in research, development, translation, and, ultimately, commercialization. Since 2009, the BU TRB has had 35 interdisciplinary trainees (15 women, 20 men; 26% minority; 97% retention; 100% employment; 5.1 years average PhD completion; 14 graduates and 20 current students, one of whom will graduate next month) who have excelled on multiple fronts, including publishing papers (99), filing patents (7), oral (47) and poster (155) presentations at local and national meetings, and participating in societal / community activities (e.g., President of the BU Student Association of Graduate Engineers, tutoring for high school students, etc.). All trainees have been supported after their TRB funding ended through independently written fellowships (one NIH NRSA F31, one NIH NRSA F30, seven NSF GRFP awards, one US Pharmacopeial Global Fellowship Award, one CIMIT Engineering Fellowship, one Glacier NSF GK12 Fellowship, one BUnano Cross- Disciplinary Fellowship, one Clare Booth Luce Fellowship, and one Ford Foundation Fellowship) or the NIH R21 / R01 grants of their mentors. In this renewal, the continuation of the TRB, with eight trainees per year funded via NIH, is aligned with the expertise of participating faculty, the availability of a large and strong applicant pool eligible for and interested in the TRB program, and an extramural funding base to provide the appropriate research environment and continued support for NIH trainees beyond their first two years supported by the TRB.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma
R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma
The Conundrum of Absentee Receptors: Efficacy Potentiation Through Drug-Receptor Modulation
Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder
海外基金